Question:
This is good news to say the least... a vaccine is on theway...in a few years everyone will live a lot longer, andhealthier... it will be found that getting rid of amyloidswill also reverse most type 2 diabetes... but thats just frommy own trials on myself. Harvard Univ is on that trailthough with mice and finding thats the case.

What does this mean to you? Dont plan on retiring until wellpast 80 because you wont want to.... if your wits are startingto get dull now and your stamina is flagging... that can bedramatically reversed even from the later stages.

Can anyone give me some ideas ???

Answer: I personally think that Alzheimer's Vaccine Research Back On Track is very good one.

Researchers at the University of Michigan have started a new,albeit modified, trial, even while the May 10 issue ofNeurology publishes follow-up data to an Alzheimer's vaccinetrial that was halted due to safety concerns in 2002.

The earlier trial was halted after about 6 percent ofparticipants developed a dangerous brain inflammation,encephalitis. However, researchers continued to monitor theremaining patients for up to a year after their lastinjection -- with some encouraging results.

Participants whose immune systems had mounted a high antibodyresponse to beta-amyloid levels in the brain performed betteron memory tests than people who had received a placebo, theMichigan team reported.

They also experienced an unexpected decrease in brain size,perhaps linked to clearance of disease-causing proteins fromthe brain.

"It's really the publication of what was presented at theAlzheimer's Association meeting in July of last year," saidDr. Sam Gandy, vice president of the Alzheimer's Association'sMedical and Scientific Advisory Council.

"The trend is in the right direction. There were somestatistically significant improvements on someneuropsychological measures, but they were not obviouslymeaningful at the bedside," he said.

All of this work, including the new trial, are based on theso-called 'amyloid theory' of Alzheimer's disease, whichhypothesizes that rising levels of beta-amyloid proteindeposited in the brain are at the root of the disease.

"It's a very popular hypothesis, and the only way to provewhether it's right or wrong is to develop an effectiveanti-amyloid strategy, expunge amyloid from the brain and seeif people never get Alzheimer's or get better," Gandy said.

So far, the evidence has remained unclear.

In the halted trial, about 20 percent (59) of the 300participants who received at least one injection developedsignificant quantities of antibodies against beta amyloid intheir blood.

In general, those who developed antibodies also displayedstabilization of memory and scored better on certainneuropsychological tests evaluating memory than the placebogroup. Furthermore, among those patients who did developantibodies, those who produced relatively high levels achievedbetter results on memory tests than those who developed lowerlevels.